Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 600 participants.

Also called NCT04168203

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04168203
Other papers using this trial's data
  • Apixaban for Extended Treatment of Provoked Venous Thromboembolism The New England journal of medicine, 2025-09-25 DOI, PubMed 40888734

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04168203. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2023-11-30 (actual). Results posted on 2025-09-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Acronym
HI-PRO
Condition
Venous Thromboembolism
Intervention (Drug)
Apixaban 2.5 MG
Intervention (Drug)
Placebo oral tablet
Lead sponsor
Brigham and Women's Hospital (class: other)

Record details

Record id
cardio:ct-nct04168203
Content hash
c64f454cf97c9f6c7b967b249cfe7c47f44cbc20a0776b27bf639719d904496a